Interleukin-3 and pregnancy loss in antiphospholipid syndrome

Scandinavian Journal of Rheumatology, Supplement

Volumn 27, Issue 107, 1998, Pages 19-22

  Shoenfeld, Y ^a,b,d   Sherer, Y ^c   Fishman, P ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HASHARON HOSPITAL   (Israel)

^d Department of Medicine B ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIPROFLOXACIN; INTERLEUKIN 3;

ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; FEMALE; HUMAN; NONHUMAN; PREGNANCY DISORDER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; PREGNANCY; REVIEW; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERLEUKIN-3; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY;

EID: 0031694846     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009742.1998.11720701     Document Type: Conference Paper

References (25)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13:486-9.
2. Harris EN. A reassessment of the antiphospholipid syndrome. J Rheumatol 1990; 17:733-5.
3. Rote NS. Antiphospholipid antibodies and disorders of pregnancy. J Clin Immunoassay 1990; 13:34-42.
4. Shoenfeld Y. Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 1994; 26:3211-3.
5. Fishman P, Shoenfeld Y. Cytokines, interleukin-3 and autoimmunity. Isr J Med Sci 1993; 29:159-64.
6. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990; 49:480-6.
7. Debili N, Hegyi E, Navarro S, Katz A, Mouthon MA, Breton-Govius J, et al. In vitro effects of hematopoietic growth factors on the proliferation, endoreplication and maturation of human megakaryocytes. Blood 1991; 77:2326-38.
8. Lellouche F, Falcon C, Carrers LO, Maclouf J. Selective inhibition of platelet-derived thromboxane A: in patients with lupus anticoagulant using low dose aspirin as assessed by enzyme immunoassay. Adv Prostagland Thrombox Leuk Res 1991; 21B:611-4.
9. Mayer P, Valent P, Schmidt G, Liehl E, Bettelheim P. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF responsive progenitors in non-human primates. Blood 1989; 74:613-21.
10. Lala PK, Graham CH. Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev 1990; 9:3669-79.
11. Hamilton JA, Vairo G, Knight KR, Cocks BG. Activation and proliferation signals in murine macrophages. Biochemical signals controlling the regulation of macrophage urokinase-type plasminogen activator activity by colony stimulating factors and other agents. Blood 1991; 77:616-27.
12. Shoenfeld Y, Blank M, Fishman P. Antiphospholipid syndrome: from the laboratory bench to the patients bedside. Lupus 1995; 4(Suppl. 1):33-6.
13. Aihanassakis I, Bleackkly RC, Paeykau V, Guilbert L, Barr PJ, Wegmann TG. The immunostimulatory effect of T cells and T cell lymphokines on murine fetally derived placental cells. J Immunol 1987; 138:37-42.
14. Fishman P, Shoenfeld Y, Hart J, Zigelman R, Shamir Y, Feldberg D, et al. Interleukin-3-like activity levels in pregnant women: possible modulation by progesterone. J Reprod Immunol 1992; 22:211-6.
15. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Tincani A, Dicker D, et al. Aspirin-interleukin-3 interrelationship in patients with anti-phospholipid syndrome. Am J Reprod Immunol 1996; 35:80-4.
16. Fishman P, Bakimer R, Blank M, Sredni D, Djaldetti M, Shoenfeld Y. The putative role of cytokines in the induction of primary anti-phospholipid syndrome in mice. Clin Exp Immunol 1992; 90:266-70.
17. Fishman P, Kamashta M, Ehhrenfeld M, Vianna J, Hughes GRV, Sredni D, et al. Interleukin-3 immunoassay in systemic lupus erythematosus patients: preliminary data. Int Arch Allergy Immunol 1993; 100:215-8.
18. Chaouat G, Menu E, Clark DA, Dy M, Minkowski M, Wegmann TG. Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. Reprod Fertil 1990; 89:447-58.
19. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91:1834-7.
20. Krause I, Blank M, Guilburd B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 1993; 29:155-61.
21. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action by aspirin-like drugs. Nature 1971; 231:232-5.
22. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Rudniki C, Shoenfeld Y. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 1995; 22:1086-90.
23. Fishman P, Shoenfeld Y. Aspirin, interleukin-3 and the antiphospholipid syndrome. Isr J Med Sci 1996; 32:13-7.
24. Blank M, George J, Fishman P, Levy Y, Toder V, Savion S, et al. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis Rheum 1998; 41:224-32.
25. Francis RB, MecGhee WG, Feinstein DI. Endothelial dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost 1988; 39:412-4.